PSTU-04 - Addressing antimicrobial resistance

Meeting room 1.60 Tuesday 3 September 2024, 11:00-12:30

Organised by the FIP Social and Administrative Pharmacy in collaboration with the FIP Hospital Pharmacy Section, the FIP Health and Medicines Information Section and the FIP Industry Pharmacy Section

Chair(s)

Ms Katharine Cresswell, National Institute for Health and Care Excellence (NICE), UK

Introduction

In 2019, 4.95 million deaths were associated with drug-resistant bacterial infections and 1·27 million deaths worldwide were directly attributed to antimicrobial resistance (AMR) making it a top global health threat. To tackle a threat as substantial as AMR, multiple interventions are needed to target the factors contributing to it. Some interventions being explored are point-of-care diagnostics to guide antimicrobial prescribing and the development of new treatment regimens as alternatives to existing treatments. Furthermore, “pull-incentives” are being explored and implemented to incentivise pharmaceutical developers to develop new antimicrobial drugs by providing a known return on investment and reward successful development of novel drugs. However, are these initiatives enough and are they moving at a pace commensurate to the threat? While this is a global threat are countries working together towards effective and cost-effective global solutions? Would initiatives like pull incentives for antimicrobials be transferable to diagnostics to incentivise their use to guide antimicrobial prescribing?

This panel will discuss different approaches being explored to tackle AMR presenting examples of multistakeholder consortium projects focused on addressing AMR, whether pull incentives for antimicrobials are transferable to diagnostics and if interventions for AMR are being implemented in a manner and at the pace needed.

Programme

11:00 – 11:05	Introduction by the chair
11:05 – 11:30	European Commission funded projects encouraging diagnostics for AMR and antimicrobial development of tuberculosis treatments Prof. Dalia Dawoud, National Institute for Health and Care Excellence (NICE), UK
11:30– 11:55	How genomics revolutionised the fight against AMR Prof. Ramy Karam Aziz, Cairo University, Egypt
11:55 – 12:25	Panel discussion
12:25 – 12:30	Closing

Learning objectives

To understand the importance of developing new antimicrobials to address the issue of antimicrobial resistance.
To appreciate the role of incentives in encouraging the development of new antimicrobials.
To communicate the value of point-of-care diagnostics and their use to ensure the appropriateness of antibiotic prescribing.

Take home messages

Efforts to combat antimicrobial resistance (AMR) should be multifaceted and include both the development of new antimicrobials and their appropriate and rational use.